about
Systemic side effects of eye drops: a pharmacokinetic perspectiveEffects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative StudyStanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.Effect of topical anti-glaucoma medications on late pupillary light reflex, as evaluated by pupillometry.Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma.Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study.A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction.Regulation of Aqueous Humor Dynamics by Hydrogen Sulfide: Potential Role in Glaucoma Pharmacotherapy.The Water-Drinking Test Revisited: An Analysis of Test Results in Subjects with Glaucoma.Prospective Evaluation of Two iStent® Trabecular Stents, One iStent Supra® Suprachoroidal Stent, and Postoperative Prostaglandin in Refractory Glaucoma: 4-year Outcomes.Reoptimization of the Organocatalyzed Double Aldol Domino Process to a Key Enal Intermediate and Its Application to the Total Synthesis of Δ -Prostaglandin J
P2860
Q28066720-F3700939-A4C1-4EBE-99CA-58706B511A0CQ28548224-F9EBB280-3C76-4C11-8AA6-DDAB3EC774C1Q33727601-2F2AD9B8-05EA-4A8C-9C7D-D0FF6D536EECQ35550289-6C083837-6AE2-42E6-B080-C690ED512EBFQ35949978-A0596B15-A28A-441D-AFBE-288DDD7B6D19Q36908446-B76CF444-99EC-4D2B-8290-E7D9F6B18B5DQ37250462-36090874-4F92-421B-BCAA-CD592797A1FBQ37349182-529EEE4B-EFE8-42A5-8C7E-0E1E75EF8C94Q37722712-2B6F725F-4236-4DBA-882D-F7A564981BCBQ46245972-D6140CBB-037A-441A-AEEA-75944379A270Q47754930-05BF477C-2A2D-4A19-8298-67A356180923Q51409446-4A79AD74-5D99-4F2E-B5F2-1C2D6F6F6B7CQ57214912-B5D629B3-420E-4E09-8AA9-9C5D1A1F31B1
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Latanoprost in the treatment of glaucoma.
@en
type
label
Latanoprost in the treatment of glaucoma.
@en
prefLabel
Latanoprost in the treatment of glaucoma.
@en
P2860
P356
P1476
Latanoprost in the treatment of glaucoma.
@en
P2093
Albert Alm
P2860
P304
P356
10.2147/OPTH.S59162
P407
P577
2014-09-26T00:00:00Z